FRANKFURT (Reuters) - Europe's drugs regulator is looking into another potentially cancer-causing substance in a common blood pressure and heart drug produced in China before 2012, widening an investigation that has so far focused on batches made after 2012.
Blood pressure drug valsartan, produced by China's Zhejiang Huahai Pharmaceutical, was this year found to contain traces of N-nitrosodimethylamine (NDMA), a probable human carcinogen, due to a production change in 2012. The findings have prompted recalls in more than 50 countries.
